Legacy Healthcare's CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
EPALINGES, Switzerland, Oct. 13, 2026 /PRNewswire/ -- Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to CINAINU® (LH-8), its...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Résiliable à tout moment · 99 $ CA/mois


